

ESMO 2021 Industry Satellite Symposium

“A Global Perspective on the Management of Neuroendocrine Tumors – the Evolving Role of Targeted Radionuclide Diagnostics and Therapy”

Friday, September 17, 2021, 10:30-12:00 (CEST), Channel 3

Chair: Raj Srirajaskanthan, MD, FRCP, King’s College Hospital, London, UK



Welcome & Introduction

Raj Srirajaskanthan, MD, FRCP
King’s College Hospital, London, UK
(live, 5 mins)



Changes in the Incidence and Prevalence of NETs – Impact of New Diagnostic Paradigms

Simron Singh, MD, MPH
Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Canada
(20 mins)



The Evolution of Guidelines for the Treatment of NETs

Namrata Vijayvergia, MD, FACP
Fox Chase Cancer Center, Philadelphia, U.S.
(20 mins)



The Role of Targeted Radionuclide Therapy in Clinical Trials

Grace Kong, MBBS (Hons), FRACP, FAANMS
Peter MacCallum Cancer Centre, Melbourne, Australia
(20 mins)

Q&A and Closing Remarks

(live, 25 mins)